Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death‐1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105‐204)
Zheng, Yulong ; Zhu, Jianqing ; Xiong, Jianping ; Jiang, Ou ; Wang, Hong ; Xie, Yanru ; Zhou, Yuefen ; Xu, Nong
Cancer, 2024-06, Vol.130 (12), p.2180-2190 [Periódico revisado por pares]United States: Wiley Subscription Services, Inc
Texto completo disponível